IMUX, US4525EP2001

H.C. Wainwright sets USD 22.00 target for Immunic stock

Published on 10/24/2026 at 21:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 11, 2026. Immunic stock costs EUR 6.61 on October 24, 2026, up 0.15 percent versus the Tradegate close of October 23, 2026.

Analyst target and reporting date

H.C. Wainwright reiterated a Buy rating and set a USD 22.00 target on October 22, 2026.
Immunic reported a USD 34.1 million GAAP net loss for the second quarter of 2026 and held USD 155.1 million in cash.
Immunic stock costs EUR 6.61 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, 0.15 percent above the Tradegate close of October 23, 2026.
Immunic is scheduled to report third-quarter 2026 results on November 11, 2026.

IMUX, US4525EP2001, Illustration mit AI erstellt.

Immunic (US4525EP2001) carries a fresh USD 22.00 price target after H.C. Wainwright reiterated its Buy rating on October 22, 2026. The target is 196.90 percent above the Nasdaq price of USD 7.41 on October 23, 2026. Immunic stock was at EUR 6.61 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, up 0.15 percent versus the Tradegate close of October 23, 2026 at EUR 6.60.

Target meets a costly development stage

According to Markets Insider on October 22, 2026, H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and set the USD 22.00 target. The same report said Immunic posted a GAAP net loss of USD 34.1 million for the quarter ended June 30, 2026, compared with USD 26.82 million in the year-earlier quarter.

The financial profile remains typical of a clinical-stage biotechnology company. Immunic held USD 155.1 million in cash on June 30, 2026, while operating cash flow was negative USD 31.0 million in the second quarter of 2026.

Price position against the yearly range

On Nasdaq, Immunic last traded at USD 7.41 on October 23, 2026 at 4:00 p.m. EDT. The stock sits between a 52-week low of USD 5.06 and a high of USD 17.43, placing the latest Nasdaq price 46.44 percent above the low and 57.49 percent below the high.

Market capitalization was USD 101.1 million as of October 23, 2026. The negative earnings profile also leaves the trailing price-to-earnings ratio at minus 1.65, according to the company-specific market figures available for that date.

November results set the next date

ChartMill lists November 11, 2026 as the next earnings date and expects a third-quarter adjusted earnings-per-share loss of USD 0.96. The date gives investors the next fixed checkpoint for cash use, trial progress and the companys path toward late-2026 clinical milestones.

EQS Group reported on October 21, 2026 that Immunic presented four clinical, biomarker and preclinical posters at MSToronto2026. The release said the Phase 3 ENSURE trials in relapsing multiple sclerosis were fully enrolled, with top-line results expected by year-end 2026.

Cash and clinical milestones matter

For investors, the key balance is the USD 155.1 million cash position against a USD 31.0 million quarterly operating cash outflow. The next earnings release can therefore add detail on runway and trial spending, while the USD 22.00 target remains a sharply higher external valuation marker than the latest Nasdaq price.

Immunic stock was trading at EUR 6.61 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST, 0.15 percent above the Tradegate close of October 23, 2026 at EUR 6.60. The further course of trading is shown by the continuously updated real-time quote of Immunic stock.